Akari Therapeutics (AKTX) Long-Term Debt Issuances (2014 - 2015)
Akari Therapeutics (AKTX) posted quarterly Long-Term Debt Issuances of $529935.0 for Q4 2015, up 24.65% year-on-year from $425148.0 in Q4 2014, and down 78.99% on a QoQ basis from $2.5 million in Q3 2015.
Akari Therapeutics (AKTX) Long-Term Debt Issuances (2014 - 2015) Analysis & Trends
Akari Therapeutics (AKTX) has reported Long-Term Debt Issuances for 2 consecutive years, with $529935.0 the latest figure, recorded in Q4 2015.
- Quarterly Long-Term Debt Issuances rose 24.65% year-over-year to $529935.0 in Q4 2015, while the trailing twelve-month figure through Dec 2025 was $529935.0 (down 82.64% YoY) and the FY2025 annual result came in at $2.1 million, up 109.9% from the prior year.
- Long-Term Debt Issuances declined to $529935.0 in Q4 2015 per AKTX's latest filing, from $2.5 million in the prior quarter.
- Over the last five years, Long-Term Debt Issuances for AKTX reached as high as $2.5 million in Q3 2015 and fell as low as $425148.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 529,935.00 |
| Dec 31, 2015 | 529,935.00 |
| Sep 30, 2015 | 2.52 Mn |
| Sep 30, 2015 | 2.52 Mn |
| Dec 31, 2014 | 425,148.00 |
| Dec 31, 2014 | 425,148.00 |